Literature DB >> 19029058

Glial cells as players in parkinsonism: the "good," the "bad," and the "mysterious" glia.

Maria A Mena1, Justo García de Yébenes.   

Abstract

The role of glia in Parkinson's disease (PD) is very interesting because it may open new therapeutic strategies in this disease. Traditionally it has been considered that astrocytes and microglia play different roles in PD: Astroglia are considered the "good" glia and have traditionally been supposed to be neuroprotective due to their capacity to quench free radicals and secrete neurotrophic factors, whereas microglia, considered the "bad" glia, are thought to play a critical role in neuroinflammation. The proportion of astrocytes surrounding dopamine (DA) neurons in the substantia nigra, the target nucleus for neurodegeneration in PD, is the lowest for any brain area, suggesting that DA neurons are more vulnerable in terms of glial support than any neuron in other brain areas. Astrocytes are critical in the modulation of the neurotoxic effects of many toxins that induce experimental parkinsonism and they produce substances in vitro that could modify the effects of L-DOPA from neurotoxic to neurotrophic. There is a great interest in the role of inflammation in PD, and in the brains of these patients there is evidence for microglial production of cytokines and other substances that could be harmful to neurons, suggesting that microglia of the substantia nigra could be actively involved, primarily or secondarily, in the neurodegeneration process. There is, however, evidence in favor of the role of neurotoxic diffusible signals from microglia to DA neurons. More recently a third glial player, oligodendroglia, has been implicated in the pathogenesis of PD. Oligodendroglia play a key role in myelination of the nervous system. Recent neuropathological studies suggested that the nigrostriatal dopamine neurons, which were considered classically as the primary target for neurodegeneration in PD, degenerate at later stages than other neurons with poor myelination. Therefore, the role of oligodendroglia, which also secrete neurotrophic factors, has entered the center of interest of neuroscientists.

Entities:  

Mesh:

Year:  2008        PMID: 19029058     DOI: 10.1177/1073858408322839

Source DB:  PubMed          Journal:  Neuroscientist        ISSN: 1073-8584            Impact factor:   7.519


  48 in total

1.  Blockade of astrocytic glutamate uptake in rats induces signs of anhedonia and impaired spatial memory.

Authors:  Anita J Bechtholt-Gompf; Hali V Walther; Martha A Adams; William A Carlezon; Dost Ongür; Bruce M Cohen
Journal:  Neuropsychopharmacology       Date:  2010-06-09       Impact factor: 7.853

Review 2.  Astrocytes in neurodegenerative disease.

Authors:  Hemali Phatnani; Tom Maniatis
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-04-15       Impact factor: 10.005

3.  Stratification of astrocytes in healthy and diseased brain.

Authors:  Alexei Verkhratsky; Robert Zorec; Vladimir Parpura
Journal:  Brain Pathol       Date:  2017-09       Impact factor: 6.508

4.  Astroglia in neurological diseases.

Authors:  Alexei Verkhratsky; José J Rodríguez; Vladimir Parpura
Journal:  Future Neurol       Date:  2013-03-01

Review 5.  Deep brain stimulation: are astrocytes a key driver behind the scene?

Authors:  Albert J Fenoy; Laurent Goetz; Stéphan Chabardès; Ying Xia
Journal:  CNS Neurosci Ther       Date:  2014-01-24       Impact factor: 5.243

Review 6.  Metabolic Dysfunction in Parkinson's Disease: Bioenergetics, Redox Homeostasis and Central Carbon Metabolism.

Authors:  Annadurai Anandhan; Maria S Jacome; Shulei Lei; Pablo Hernandez-Franco; Aglaia Pappa; Mihalis I Panayiotidis; Robert Powers; Rodrigo Franco
Journal:  Brain Res Bull       Date:  2017-03-21       Impact factor: 4.077

7.  PATHOBIOLOGY OF NEURODEGENERATION: THE ROLE FOR ASTROGLIA.

Authors:  Alexei Verkhratsky; Robert Zorec; Jose J Rodriguez; Vladimir Parpura
Journal:  Opera Med Physiol       Date:  2016-03-04

8.  Withania somnifera alleviates parkinsonian phenotypes by inhibiting apoptotic pathways in dopaminergic neurons.

Authors:  Jay Prakash; Shikha Chouhan; Satyndra Kumar Yadav; Susan Westfall; Sachchida Nand Rai; Surya Pratap Singh
Journal:  Neurochem Res       Date:  2014-11-18       Impact factor: 3.996

Review 9.  Flavonoids and astrocytes crosstalking: implications for brain development and pathology.

Authors:  Jader Nones; Joice Stipursky; Sílvia Lima Costa; Flávia Carvalho Alcantara Gomes
Journal:  Neurochem Res       Date:  2010-03-09       Impact factor: 3.996

10.  Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease.

Authors:  Marianna Sikorska; Patricia Lanthier; Harvey Miller; Melissa Beyers; Caroline Sodja; Bogdan Zurakowski; Sandhya Gangaraju; Siyaram Pandey; Jagdeep K Sandhu
Journal:  Neurobiol Aging       Date:  2014-04-02       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.